Publicacións en colaboración con investigadores/as de Hospital Costa Del Sol (11)

2024

  1. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

  2. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology

  3. Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 171-177

2023

  1. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study

    Melanoma research, Vol. 33, Núm. 5, pp. 388-397

  2. Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

    Clinical and Translational Oncology, Vol. 25, Núm. 10, pp. 3021-3031

  3. Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma

    Cancer, Vol. 129, Núm. 16, pp. 2581-2592

2019

  1. SEOM clinical guidelines to primary prevention of cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 106-113

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

  2. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2016

  1. Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location

    Clinical and Translational Oncology, Vol. 18, Núm. 11, pp. 1114-1122

2014

  1. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

    Bone, Vol. 68, pp. 32-40